1 - 28 of 28
Dr. Hakonarson is director of the Center for Applied Genomics and professor of Pediatrics at the Perelman School of Medicine, University of Pennsylvania. He leads a $40 million commitment from Children’s Hospital of Philadelphia to genomically characterize approximately 100,000 children, an initiative that has gained nationwide attention in the Wall Street Journal, New York Times, Time Magazine, Nature, and Science.
Dr. Hamilton studies intestinal epithelial cells and how they help maintain human health. Although there is a great deal understood about how these cells function, little is known about how they behave during disease. Dr. Hamilton focuses on defining new mechanisms in regenerative medicine, inflammatory bowel disease, and colorectal cancer.
Dr. Hartung's clinical and translational research program focuses on autosomal recessive polycystic kidney disease and other genetic kidney diseases, development of new kidney and liver imaging biomarkers, and neurocognitive outcomes in children with chronic kidney disease.
Dr. Heuckeroth investigates mechanisms controlling bowel motility in order to find new ways to treat, diagnose, and prevent intestinal motility disorders. He works to define genetic, biochemical, and cellular processes that impact bowel function, with a special interest in the enteric nervous system and intestinal smooth muscle cells.
Dr. Hill seeks to understand how the immune system contributes to the two most common chronic diseases of childhood: allergy and obesity. He uses clinical and epidemiological information to guide basic and translational research on the genetic, epigenetic, and immunologic basis of these important conditions.
Dr. Hill’s research interests include identifying strategies to help parents, children, and healthcare providers cope with stressful situations; coping skills in the context of serious illness; how parents develop new goals when a child’s health is declining; good parent beliefs of parents of seriously ill children; and changes in self-concept for parents caring for a child with a life-threatening illness.
Dr. Hocking’s research aims to better understand the neurodevelopmental consequences of having survived childhood cancer or having neurofibromatosis type 1, to identify those who are most at risk for poor outcomes, and to intervene in some way in order to improve quality of life.
Developing and implementing strategy to lead the operations of the research-related regulatory, compliance, and safety programs across all types of research including human, animal, and laboratory-based research.
Dr House is an Emergency Department attending with a dual interest in medical education and ED operations and flow. She works with a team to improve throughput in teams of the ED and reduce patient wait times. She also is the director of the Emergency Medicine lecture series.
Dr. Hunger's focuses his research on molecular and genomic approaches to identify and clinically evaluate targeted cancer treatments for children with relapsed or high-risk acute lymphoblastic leukemia (ALL) such as Philadelphia chromosome-like (Ph-Like) ALL. The long-term goal of Dr. Hunger’s research is to develop better therapies, improve cure rates, and minimize treatment toxicities for children with ALL.